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Abstract: 
 
Animal allergens are an important cause of asthma and allergic rhinitis. We designed and tested a 
chimeric human-cat fusion protein composed of a truncated human IgG Fcγ1 and the major cat 
allergen Fel d1, as a proof of concept for a new approach to allergy immunotherapy. This Fcγ-
Fel d1 protein induced dose-dependent inhibition of Fel d1-driven IgE-mediated histamine 
release from cat-allergic donors' basophils and sensitized human cord blood-derived mast cells. 
Such inhibition was associated with altered Syk and ERK signaling. The Fcγ-Fel d1 protein also 
blocked in vivo reactivity in FcεRIα transgenic mice passively sensitized with human IgE 
antibody to cat and in Balb/c mice actively sensitized against Fel d1. The Fcγ-Fel d1 protein 
alone did not induce mediator release. Chimeric human Fcγ-allergen fusion proteins may provide 
a new therapeutic platform for the immune-based therapy of allergic disease. 
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Article: 
 
Traditionally, immune-based therapy for inhalant allergens relies upon frequent injection of 
gradually increasing amounts of allergens. This approach is time-consuming, protracted and 
marred by serious treatment reactions. Immunotherapy for life-threatening food allergy (e.g., 
peanut allergy) has proven unsuccessful1. Allergen-induced IgE-driven mediator release from 
mast cells and basophils is a key contributor in asthma, allergic rhinitis and severe food 
reactions2. Cross-linking mast cell and basophil FcεRI by multivalent antigen activates tyrosine 
phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the β- and γ-
FcεRI subunit cytoplasmic tails, thereby initiating downstream signaling through Syk3. Mast 
cells and basophils also express FcγRIIb, which contains a single conserved immunoreceptor 
tyrosine-based inhibition motif (ITIM) within its cytoplasmic tail4,5. Studies indicate that 
aggregating FcγRIIb to FcεRI leads to rapid tyrosine phosphorylation of the FcγRIIb ITIM 
tyrosine by FcεRI-associated Lyn and inhibition of FcεRI signaling6,7,8,9. Experiments using a 
human Ig Fcγ-Fcε fusion protein that directly cross-links FcεRI and FcγRIIb on human basophils 
support this hypothesis10,11,12,13. We have developed and tested a new form of immune therapy 
based on a chimeric fusion protein (GFD) comprised of the human Fcγ plus the cat (Felis 
domesticus) allergen14 Fel d1. This molecule is specifically designed to coaggregate FcγRIIb 
with FcεRI-bound IgE, thereby inhibiting mediator release while serving as allergen 
immunotherapy that could be given as a safe series of high-dose injections. 
 
We cloned human IgGγ1 constant region genomic DNA from the hinge through the CH3 domain 
into a mammalian expression vector with a cytomegalovirus promoter and a mouse 
immunoglobulin κ-chain leader sequence. We placed the cDNA encoding a Fel d1 construct15 
containing both chain 1 and chain 2 after the CHγ3 domain with a 15–amino acid (Gly4Ser)3 
linker16 between Fcγ1 and Fel d1. The fusion protein contained the binding site for FcγRII17. The 
Fcγ1-Fel d1 fusion protein was expressed as the predicted dimer of 140 kDa. Western blot and 
ELISA testing showed that antibodies to human gamma chain and Fel d1 recognize GFD. GFD 
binding to the human FcγRII was shown using HMC-1, a human mast cell–like line that 
expresses FcγRII but not FcεRI18. GFD bound to FcγRII in a fashion equivalent to human IgG, 
as assessed by flow cytometry. ELISA results indicate that specific IgE from cat-allergic 
patients' sera recognized GFD (data not shown). These results show that GFD is properly folded, 
has preserved FcR binding and is recognized by human IgE antibody to cat. 
 
We purified basophils from cat-allergic subjects19 and cultured them with 1 ng/ml to 1 μg/ml of 
GFD. Purified human IgG served as a control. Two hours later, we centrifuged the cells and 
assayed the histamine in supernatants as 'prerelease.' We then washed and challenged the cells 
with an optimal dose of Fel d1 (1.0 μg/ml) for 30 min and measured the resulting histamine 
release. GFD inhibited release by more than 75% (P< 0.002) at 10 ng/ml, whereas at 100 ng/ml 
inhibition was >90% (P < 0.001) (Fig. 1a). Results without autologous serum during the first 
incubation were similar, except overall histamine release was about 15% less. We observed 
similar inhibition in cat allergen–sensitized cord blood–derived mast cells wherein GFD (10 
μg/ml) reduced degranulation by an average of 77% (P < 0.05) (Fig. 1b). Thus, GFD inhibited 
allergen-driven histamine release in a dose-dependent fashion. Notably, these results also show 
that GFD does not function as an allergen because mediator prerelease was not observed with 
GFD-incubated cat allergen–sensitized basophils. 
 
Tyrosine phosphorylation is a key event connecting FcεRI cross-linking to downstream signaling 
in human mast cells and basophils. IgE stimulation in human FcεRI-positive cells quickly leads 
to phosphorylation of ERK1/2 and Syk12,20. Cross-linking FcεRI on cord blood mast cells with 
IgE directed to Fel d1 induces substantial tyrosine phosphorylation of Syk and ERK, which was 
markedly reduced in cells preincubated with GFD (Fig. 2). We observed inhibition 2 min after 
antigen stimulation; inhibition persisted for 15 min. Thus, GFD coaggregation of FcεRI and 
FcγRII through an Fcγ-Fel d1-IgE linkage inhibits IgE-mediated Syk and ERK phosphorylation, 
which probably contributes to inhibition of basophil and mast cell function. 
 
 
Figure 1: GFD inhibits human basophil and mast cell degranulation. Basophils from an atopic donor (a) or cat 
serum–sensitized, cord blood–derived mast cells (b) were incubated for 2 h with GFD and the supernatant assayed 
for prerelease of histamine (a) or β-hexosaminidase (b). Washed cells were challenged with Fel d1 and histamine or 
β-hexosaminidase measured in the supernatant (Fel d1 release). Nonspecific human IgG (hIgG) and IgE (hIgE) were 
used as controls. The results from one experiment are representative of three separate experiments. The asterisk 
indicates a statistically significant difference when comparing the two conditions. *P < 0.05. 
 
Transgenic mice expressing the human FcεRIα chain (hFcεRIα+ mice) show allergic reactivity 
after administration of human IgE antibody and challenge with the appropriate antigen21,22. Mast 
cells in these transgenic mice also express the mouse FcγRIIb that can bind human IgG. Using 
passive cutaneous anaphylaxis (PCA) in the hFcεRIα+ mice, we tested the predicted inhibitory 
effects of GFD by co-cross-linking the humanized FcεRI and the mouse FcγRIIb. 
 
We primed transgenic mice (n = 12) intradermally with human serum containing high-titer IgE 
antibody to Fel d1 (118 kU/L) and measured PCA reactivity at sites injected with varying doses 
of GFD, after intravenous challenge with purified Fel. We measured each PCA reaction as the 
size of blue staining reaction of the skin at 30 min. GFD at 100 ng/spot consistently and 
completely blocked PCA reactivity (Fig. 3a). The GE2 fusion protein, which directly crosslinks 
FcεRI-FcγRII23 gave analogous inhibition (Fig. 3b). GFD blocked PCA reactivity with 10-fold 
greater efficiency compared to GE2 (Fig. 3b). GFD blocked PCA reactivity equally well when 
injected 4 h after or simultaneously with cat-allergic donors' serum (Fig. 3b). PCA reactivity of 
purified cat-allergic donors' serum was destroyed by heat inactivation at 56 °C for 30 min23 (data 
not shown). To test the specificity of GFD, we sensitized hFcεRIα+ mice with chimeric human 
IgE antibody to NP (4-hydroxy-3-nitrophenylacetyl) and induced PCA reactivity by intravenous 
challenge with NP–bovine serum albumin. GFD did not block IgE-induced reactivity to NP (data 
not shown). These data show that the GFD specifically inhibits cat allergen–induced IgE-
mediated mediator release in vivo. To prove that GFD was not functioning as an allergen, we 
gave mice Evans blue dye 15 min after local administration of GFD at sites initially injected with 
cat-allergic donors' serum or purified IgE from cat-allergic subjects' serum (data not shown). We 
observed no reaction as evidenced by lack of dye extravasation, which shows that GFD itself did 
not induce mast cell release and such an effect does not account for the failure of GFD-treated 
sites to react upon later systemic allergen challenge. 
 
 
Figure 2: GFD inhibits FcεRI-mediated Syk and ERK phosphorylation. Cord blood–derived mast cells were 
sensitized with cat-allergic donors' serum, washed, activated as described, and western blotted with the indicated 
antibodies. The top panel (Syk) represents an independent experiment from the bottom panel (Erk). Results are 
representative of at least three separate experiments. 
 
We developed a model of systemic reactivity to Fel d1 in actively sensitized Balb/c mice to test 
the immunotherapeutic potential of GFD. The value of this model is based on the binding of 
human Fcγ by the mouse FcγRs11 (data not shown). Thus, the Fcγ portion of GFD binds to 
mouse FcγRs, including FcγRIIb, and drives inhibitory signaling through its ITIM motif. 
Simultaneously, the Fel d1 portion of GFD will bind to mouse Fel d1-specific IgE and/or IgG1 
on the surface of sensitized mast cells or basophils with the expectation that GFD-mediated 
cross-linking of these FcεRIs and FcγRs will generate a negative signal for mast cells or 
basophils. 
 
We sensitized BALB/c mice with Fel d1 and treated them up to day 21 (Fig. 4a). GFD treatment 
completely blocked Fel d1-induced airway hyper-responsiveness at days 30 (Fig. 4b) and 44 
(data not shown), assessed by increased pulmonary resistance after methacholine challenge. 
Similarly, we observed blunted eosinophilic airway inflammation in Fel d1-sensitized and 
intratracheally challenged mice, evident as decreased eosinophils in bronchoalveolar lavage fluid 
after GFD treatment (Fig. 4c). Using a sensitization and GFD immunotherapy model that used 
intense Fel d1 sensitization, we tested GFD for its ability to block systemic allergic reactivity as 
indicated by a decrease in challenged animals' core body temperature24. Core temperatures 
dropped an average of 1.7±0.2 °C over the hour after intratracheal Fel d1 challenge. This was 
completely blocked following GFD treatment (P < 0.001) (Fig. 4d). These results indicate that 
GFD administrated in a regime similar to allergen immunotherapy ameliorates allergic responses 
to Fel d1 in previously sensitized animals. 
 
 
Figure 3: GFD inhibits IgE-mediated degranulation in FcεRIα transgenic mice. (a) Dose-dependent inhibition of 
PCA by GFD. The skin sites were sensitized with cat-allergic donors' serum, followed by the administration of: (I) 
saline; (II–IV), GFD 1, 10 and 100 ng, respectively. (b) Comparison of GFD and GE2 for inhibiting PCA. The skin 
sites were sensitized and treated as follows: (I) saline 4 h later; (II) 100 ng GFD 4 h later; (III) 100 ng GFD 
simultaneously with serum; (IV) 1 μg GE2 simultaneously with serum; (V) 100 ng GE2 4 h later; (VI) 100 ng GE2 
simultaneously with serum. 
 
Recognition of the Fel d1 portion of GFD by cat allergen-specific IgE is predicted to lead to the 
formation of FcγR-(GFD)-IgE-FcεRI complexes on basophils and mast cells. This probably 
accounts for the ability of GFD to inhibit mediator release from basophils of cat allergen–
sensitive humans and to inhibit PCA reactivity in transgenic mice, and is analogous to what we 
found with a human bifunctional Fcγ-Fcε protein (GE2), which directly cross-links FcγRIIb and 
FcεRI to induce antigen nonspecific inhibitory signaling10,23. In contrast to GE2, GFD indirectly 
cross-links FcγRIIb and FcεRI through antigen-specific IgE and inhibits basophil and mast cell 
reactivity in an allergen-specific fashion. GFD also contains the allergen (Fel d1) that should 
induce a protective immune response, as seen with standard immunotherapy25,26 and as observed 
in mice with Fel d1-induced systemic and airway reactivity (Fig. 4). The advantage of an Fcγ-
allergen construct (e.g., GFD) versus allergen is that the chimeric protein does not drive mediator 
release. 
 
 
Figure 4: GFD blocks Fel d1-induced allergic response in mice. (a) Schematic diagram of the experimental 
protocol. (b) Inhibitory effect of GFD on Fel d1-induced AHR. The numbers represent the average values from three 
measurements of airway resistance. (c) Inhibitory effect of GFD Fel d1-induced pulmonary eosinophilic 
inflammation. Total and differential numbers of bronchoalveolar lavage fluid cells were counted. (d) Inhibitory 
effect of GFD on Fel d1-induced systemic allergic reactivity evidenced as core body temperature. Core body 
temperature change was measured at 5-min intervals immediately after Fel d1 challenge. The asterisk indicates a 
statistically significant difference between the two conditions. *P < 0.05. 
 
Overall, GFD inhibited allergen-driven IgE-mediated mediator release in vitro from human 
basophils and cord blood–derived mast cells, and in vivo from both passively cat allergen–
sensitized FcεRIα transgenic mice and in actively cat allergen–sensitized mice. Chimeric human 
Fcγ-allergen proteins such as GFD provide a new platform for antigen-specific immunotherapy 
in a host of human allergic diseases and may be a particularly powerful approach for treatment of 
severe food-induced allergy. 
 
Methods 
 
GFD construction and expression. To construct the human Fcγ-Fel d1 chimeric gene, we 
amplified cDNA encoding Fel d1 from a recombinant Fel d1 cDNA clone (chain 1 + chain 2)15. 
The 5′-end primer contained a flexible linker sequence. We cloned amplified products into 
pCR2.1 vector (Invitrogen), sequenced and inserted the Sal I-Not I fragment into pAN 
expression vector (Invitrogen pDisplay). We transfected the expression vector containing the 
new Ig Fcγ-Fel d1 chimeric gene into SP2/0 cells and purified the Fcγ-Fel d1 fusion protein in 
the culture supernatants by protein A affinity chromatography. 
 
Western blots. We ran purified GFD on SDS PAGE and transferred it to membranes where we 
probed it with either mouse antibody to human IgG (γ chain–specific) or antibody to Fel d1 and 
goat antibody to mouse IgG conjugated to horseradish peroxidase. For Syk and Erk 
measurements, we treated IgE-sensitized cord-blood mast cells with GFD or control materials, 
and followed with activation, lysis and blotting as described5. We probed blots with rabbit 
antibodies that recognize phosphorylated Syk (Cell Signaling) or mouse antibodies to 
phosphorylated ERK 1/2 (Upstate). We developed blots using enhanced chemiluminescence 
reagents (ECL, Amersham Biosciences) and exposed them to BioMax film (Eastman Kodak). 
We quantified band intensities using a molecular imaging package (Bio-Rad, Discovery Series; 
Quantity One, Quantitative Software) and presented them as a ratio of Syk or Erk to actin to 
compensate for gel loading and blot stripping-reprobing variations. 
 
Basophil and cord blood–derived mast cell purification. We collected blood from donors who 
were skin test–positive to Fel d1 and had a self-reported history of cat allergy. The basophils 
were purified by Percoll gradient centrifugation, followed by negative selection using magnetic 
beads. Basophil purities were ≥95% as determined with Wrights-Giemsa stain. Cord blood–
derived mast cells were derived as described12. We obtained informed consent for all human 
subjects as approved by the Institutional Review Board at Virginia Commonwealth University. 
 
Measurement of degranulation. We sensitized cord blood–derived mast cells with human IgE 
antibody to Fel d1 in serum from cat-allergic donors (Plasma Labs) for 24 h. After washing the 
mast cells or basophils, we added GFD (0–10 μg/ml) for 2 h at 37 °C and centrifuged the cells 
and used the supernatants to determine any mediator prerelease. We washed and activated cells 
in Tyrodes (mast cells) or DMEM (basophils), with or without optimal concentrations of Fel d1 
(Indoor Biotechnologies) (10–200 ng/ml). As a control, we substituted nonspecific human IgG 
for GFD. After 30 min, we centrifuged cells and removed the supernatant for β-hexosaminidase 
or histamine analysis, as described27. 
 
Passive cutaneous anaphylaxis. We injected transgenic mice intradermally with 50 μl of 1:5 
diluted cat allergic serum or purified IgE from that serum. We injected different doses of purified 
GFD at the same sites 4 or 24 h later. We injected GFD simultaneously with the allergic serum 
(or purified IgE) in selected experiments. We injected mice intravenously with 10 μg of purified 
Fel d1, plus Evans blue dye, 4 or 24 h later. The mice were generally killed 30 min after the 
intravenous challenge although in some experiments, this was done at 60 and 120 min to assess 
and confirm the blocking activity of GFD. 
 
Mouse models. To measure airway changes shown in Fig. 4b and 4c, we sensitized and treated 
6–8-week-old BALB/c mice using the protocol diagrammed in Fig. 4a. To assess systemic 
allergic reactivity, we sensitized mice by intraperitoneal injection with 5 μg of Fel d1 on d 1 and 
14, then boosted them intratracheally with 1 μg of Fel d1 on days 28, 29, 30 and 33. We treated 
mice subcutaneously with 5 μg of GFD or saline on days 37, 38 and 39. We subjected the mice 
then to intratracheal challenge with 1 μg of Fel d1 on day 40 (Fig. 4d) and monitored the 
animals' core temperature rectally using a rectal probe digital thermometer (YSI Inc.). We 
obtained approval from the Animal Research Committee at UCLA for all the animal experiments 
performed. 
 
Airway response to methacholine. We measured airway responsiveness 48 h after intratracheal 
challenge using a modified forced oscillation method28. We connected anesthetized mice to a 
computer-controlled small-animal ventilator (FlexiVent, SCIREQ) and calibrated it to remove 
resistance of the tracheal, cannula and tubing. We obtained measurements of pulmonary 
resistance at 10-s intervals, both before and after intravenous administration of acetyl-β-
methylcholine-chloride (1.67 μg/g body weight) by using the forced oscillatory technique with 
the conventional primewave 8 with a peak to peak amplitude of 0.17442 ml. 
 
Bronchoalveolar lavage. Two days after intratracheal challenge, the mice were killed, their 
lungs lavaged and total numbers of bronchoalveolar lavage cells counted after cells were stained 
with trypan blue. Differential cell counts measured on at least 300 cells stained with Wright-
Giemsa. 
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